Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. New strategies such as monoclonal antibody therapies. antibody-drug conjugates, immune checkpoint therapy, adoptive cell therapies such as natural killer cells, marrow infiltrating lymphocytes, dendritic cells, CAR T cell therapies and cancer vaccines represent the basis for next generation myeloma therapies. We are talking to Dr. Saad Usmani of Levine Cancer Institute / Carolinas Healthcare System about the latest advances in immunotherapy for multiple myeloma.
Most of the multiple myeloma patients become resistant to existing therapies or relapse. How long do you predict, the effects of a particular immunotherapy will last on patients before they start showing resistance.
Most of the multiple myeloma patients become resistant to existing therapies or relapse. How long do you predict, the effects of a particular immunotherapy will last on patients before they start showing resistance.